Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Operating revenue decreased 5.2% YoY, with a JPY339mn operating loss, reflecting absence of upfront and milestone payments.</li><li>Royalties increased 14.4% YoY to JPY1.2bn, driven by strong tegoprazan sales in South Korea and global rollout.</li><li>The company expects JPY4.0bn operating revenue for FY12/26, with JPY3.0bn from RaQualia and JPY1.0bn from FIMECS.</li></ul>

Operating revenue decreased 5.2% YoY, with a JPY339mn operating loss, reflecting absence of upfront and milestone payments.Royalties increased 14.4% YoY to JPY1.2bn, driven by strong tegoprazan sales in South Korea and global rollout.The company expects JPY4.0bn operating revenue for FY12/26, with JPY3.0bn from RaQualia and JPY1.0bn from FIMECS.

Raqualia Pharma (4579 JP): 1H FY12/26 flash update